Please login to the form below

Not currently logged in
Email:
Password:

Relovair on track for filing in mid-2012, says GSK

But once-daily COPD/asthma treatment still struggles to show superiority over Advair

GlaxoSmithKline (GSK) and partner Theravance have completed two more phase III trials of Relovair, their combination therapy for chronic obstructive pulmonary disease (COPD) and asthma, and say they are now gearing up to file for approval later this year.

Relovair (fluticasone furoate and vilanterol) had been developed as a follow-up to GSK's big-selling Seretide/Advair (fluticasone propionate and salmeterol) product, which achieved sales of over £5bn ($7.9bn) last year but has started to slow down.

Patent protection for Advair starts to expire in Europe next year, so GSK is hoping to have Relovair approved and bringing in revenues as quickly as possible, although it argues that the Diskus inhaler used with the product will confer a competitive advantage even after generics enter the market.

Once again however, GSK and Theravance struggled to show that Relovair was unequivocally superior to Advair in COPD.

One phase III trial in this indication showing significantly better effects on respiratory function while another showed a numerical improvement but did not reach statistical significance. That pattern mirrored earlier phase III trial results.

Relovair still has the advantage over Advair of once-daily rather than twice-daily dosing, thanks to the inclusion of 'ultra' long-acting beta agonist (LABA) vilanterol.

GSK and Theravance also said they have completed a pivotal phase III trial in asthma, designed to compare both fluticasone furoate and fluticasone propionate to placebo.

GSK said Relovair would be filed for COPD in the US and Europe in the middle of the year and will also be submitted as a new treatment for asthma in Europe at the same time.

In the US however GSK said it will "continue discussions" with the FDA on its use in asthma, in light of more stringent regulatory requirements for new asthma therapies which have followed recent concerns about the safety of LABA drugs.

26th March 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics